Janet Woodcock: FDASIA was landmark legislation in US drug regulation but sequester threatens success
This article was originally published in SRA
Executive Summary
A hearing on 15 November in the US of the House of Representatives’ Energy and Commerce Health Subcommittee1 was an opportunity for the heads of the Food and Drug Administration's drug centers to boast about the progress the agency has made in implementing FDASIA, the FDA Safety and Innovation Act. It also gave lawmakers a forum at which to crow about one of the few accomplishments they've made in the past year in the current rancorous Washington environment.
You may also be interested in...
Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House
The 2017 user fee reauthorization bill contains provisions that should be significantly easier for the agency to implement compared with the 2012 measure. Senate clears clean bill for president's review.
Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House
The 2017 user fee reauthorization bill contains provisions that should be significantly easier for the agency to implement compared with the 2012 measure. Senate clears clean bill for president's review.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.